Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever

– PRTX007 program to support DTRA’s efforts to establish biological defense solution against Lassa fever and other hemorrhagic viruses – SAN DIEGO, March 20, 2024 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, today announced that it was awarded a $22,480,552 contract by the Defense Threat Reduction Agency (DTRA) […] The post Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever appeared first on Primmune .